PSEN1 and Alzheimer disease: Interestingly, it has been demonstrated that AD patients sustain axon loss [25, 68] but the magnitude of the effects we reported (large drop in neurofilament densities, first in aged PS1 control mice and second, greatly accentuated, in aged double APPxPS1 transgenics) has not been reported up to now to the best of our knowledge.